226 related articles for article (PubMed ID: 7579052)
21. Alterations of Proximal Tubular Secretion in Autosomal Dominant Polycystic Kidney Disease.
Wang K; Zelnick LR; Chen Y; Hoofnagle AN; Watnick T; Seliger S; Kestenbaum B
Clin J Am Soc Nephrol; 2020 Jan; 15(1):80-88. PubMed ID: 31628117
[TBL] [Abstract][Full Text] [Related]
22. The relationship between magnitude of proteinuria reduction and risk of end-stage renal disease: results of the African American study of kidney disease and hypertension.
Lea J; Greene T; Hebert L; Lipkowitz M; Massry S; Middleton J; Rostand SG; Miller E; Smith W; Bakris GL
Arch Intern Med; 2005 Apr; 165(8):947-53. PubMed ID: 15851648
[TBL] [Abstract][Full Text] [Related]
23. Diuretics versus angiotensin-converting enzyme inhibitors in autosomal dominant polycystic kidney disease.
Ecder T; Edelstein CL; Fick-Brosnahan GM; Johnson AM; Chapman AB; Gabow PA; Schrier RW
Am J Nephrol; 2001; 21(2):98-103. PubMed ID: 11359016
[TBL] [Abstract][Full Text] [Related]
24. Effects of blood pressure control on progressive renal disease in blacks and whites. Modification of Diet in Renal Disease Study Group.
Hebert LA; Kusek JW; Greene T; Agodoa LY; Jones CA; Levey AS; Breyer JA; Faubert P; Rolin HA; Wang SR
Hypertension; 1997 Sep; 30(3 Pt 1):428-35. PubMed ID: 9314428
[TBL] [Abstract][Full Text] [Related]
25. Borderline hypertensive autosomal dominant polycystic kidney disease patients have enhanced production of renal dopamine. Normalization of renal haemodynamics by DOPA infusion.
Barendregt JN; Florijn KW; Muizert Y; Chang PC
Nephrol Dial Transplant; 1995; 10(8):1332-41. PubMed ID: 8538923
[TBL] [Abstract][Full Text] [Related]
26. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group.
Klahr S; Levey AS; Beck GJ; Caggiula AW; Hunsicker L; Kusek JW; Striker G
N Engl J Med; 1994 Mar; 330(13):877-84. PubMed ID: 8114857
[TBL] [Abstract][Full Text] [Related]
27. Reversal of left ventricular hypertrophy with angiotensin converting enzyme inhibition in hypertensive patients with autosomal dominant polycystic kidney disease.
Ecder T; Edelstein CL; Chapman AB; Johnson AM; Tison L; Gill EA; Brosnahan GM; Schrier RW
Nephrol Dial Transplant; 1999 May; 14(5):1113-6. PubMed ID: 10344347
[TBL] [Abstract][Full Text] [Related]
28. Patients with autosomal dominant polycystic kidney disease hyperfiltrate early in their disease.
Wong H; Vivian L; Weiler G; Filler G
Am J Kidney Dis; 2004 Apr; 43(4):624-8. PubMed ID: 15042539
[TBL] [Abstract][Full Text] [Related]
29. Kidney Function Reserve Capacity in Early and Later Stage Autosomal Dominant Polycystic Kidney Disease.
Messchendorp AL; van Londen M; Taylor JM; de Borst MH; Navis G; Casteleijn NF; Gaillard CAJM; Bakker SJL; Gansevoort RT;
Clin J Am Soc Nephrol; 2018 Nov; 13(11):1680-1692. PubMed ID: 30254028
[TBL] [Abstract][Full Text] [Related]
30. Effects of dihydropyridine calcium channel blockers, angiotensin-converting enzyme inhibition, and blood pressure control on chronic, nondiabetic nephropathies. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN).
Ruggenenti P; Perna A; Benini R; Remuzzi G
J Am Soc Nephrol; 1998 Nov; 9(11):2096-101. PubMed ID: 9808096
[TBL] [Abstract][Full Text] [Related]
31. Proteinuria predicts end-stage renal failure in non-diabetic chronic nephropathies. The "Gruppo Italiano di Studi Epidemiologici in Nefrologia" (GISEN).
Ruggenenti P; Perna A; Mosconi L; Matalone M; Pisoni R; Gaspari F; Remuzzi G
Kidney Int Suppl; 1997 Dec; 63():S54-7. PubMed ID: 9407422
[TBL] [Abstract][Full Text] [Related]
32. Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study.
Peterson JC; Adler S; Burkart JM; Greene T; Hebert LA; Hunsicker LG; King AJ; Klahr S; Massry SG; Seifter JL
Ann Intern Med; 1995 Nov; 123(10):754-62. PubMed ID: 7574193
[TBL] [Abstract][Full Text] [Related]
33. Antihypertensive treatments in adult autosomal dominant polycystic kidney disease: network meta-analysis of the randomized controlled trials.
Xue C; Zhou C; Dai B; Yu S; Xu C; Mao Z; Ye C; Chen D; Zhao X; Wu J; Chen W; Mei C
Oncotarget; 2015 Dec; 6(40):42515-29. PubMed ID: 26636542
[TBL] [Abstract][Full Text] [Related]
34. Relationship between renal volume growth and renal function in autosomal dominant polycystic kidney disease: a longitudinal study.
Fick-Brosnahan GM; Belz MM; McFann KK; Johnson AM; Schrier RW
Am J Kidney Dis; 2002 Jun; 39(6):1127-34. PubMed ID: 12046022
[TBL] [Abstract][Full Text] [Related]
35. Effect of Sirolimus on Disease Progression in Patients with Autosomal Dominant Polycystic Kidney Disease and CKD Stages 3b-4.
Ruggenenti P; Gentile G; Perico N; Perna A; Barcella L; Trillini M; Cortinovis M; Ferrer Siles CP; Reyes Loaeza JA; Aparicio MC; Fasolini G; Gaspari F; Martinetti D; Carrara F; Rubis N; Prandini S; Caroli A; Sharma K; Antiga L; Remuzzi A; Remuzzi G;
Clin J Am Soc Nephrol; 2016 May; 11(5):785-794. PubMed ID: 26912555
[TBL] [Abstract][Full Text] [Related]
36. Clinical characteristics and predictors of progression of chronic kidney disease in autosomal dominant polycystic kidney disease: a single center experience.
Ozkok A; Akpinar TS; Tufan F; Kanitez NA; Uysal M; Guzel M; Caliskan Y; Alisir S; Yazici H; Ecder T
Clin Exp Nephrol; 2013 Jun; 17(3):345-51. PubMed ID: 23085781
[TBL] [Abstract][Full Text] [Related]
37. Treatment of hypertension in chronic kidney disease.
Toto RD
Semin Nephrol; 2005 Nov; 25(6):435-9. PubMed ID: 16298269
[TBL] [Abstract][Full Text] [Related]
38. Approaches to testing new treatments in autosomal dominant polycystic kidney disease: insights from the CRISP and HALT-PKD studies.
Chapman AB
Clin J Am Soc Nephrol; 2008 Jul; 3(4):1197-204. PubMed ID: 18579674
[TBL] [Abstract][Full Text] [Related]
39. Renal structure in early autosomal-dominant polycystic kidney disease (ADPKD): The Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) cohort.
Chapman AB; Guay-Woodford LM; Grantham JJ; Torres VE; Bae KT; Baumgarten DA; Kenney PJ; King BF; Glockner JF; Wetzel LH; Brummer ME; O'Neill WC; Robbin ML; Bennett WM; Klahr S; Hirschman GH; Kimmel PL; Thompson PA; Miller JP;
Kidney Int; 2003 Sep; 64(3):1035-45. PubMed ID: 12911554
[TBL] [Abstract][Full Text] [Related]
40. Achievement and safety of a low blood pressure goal in chronic renal disease. The Modification of Diet in Renal Disease Study Group.
Lazarus JM; Bourgoignie JJ; Buckalew VM; Greene T; Levey AS; Milas NC; Paranandi L; Peterson JC; Porush JG; Rauch S; Soucie JM; Stollar C
Hypertension; 1997 Feb; 29(2):641-50. PubMed ID: 9040451
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
